目的探讨腹膜假性粘液瘤的诊断和治疗。方法对本院1988~2002年收治的5例腹膜假性粘液瘤的临床资料进行回顾性分析，并结合文献加以讨论。结果该5例患者的主要临床表现为腹胀、腹痛、腹部包块，其中4例行减瘤手术治疗，并在术后辅以腹腔内化疗。术后随访，1例3年内死亡，1例7年内死亡，另2例现已分别存活9年零5个月和3个月。结论腹膜假性粘液瘤是一种少见疾病，其来源多见于阑尾，术前诊断困难，多次针吸和血清癌胚抗原检查对诊断可能有帮助。多数患者术中探查可见腹腔内广泛病变，一次清除很困难，往往需采取多次减瘤术。外科手术治疗仍是目前有效的治疗手段。
ObjectiveTo explore the values of CA19-9, CA242, CEA, and CA125 single or combined detection on clinical diagnosis and prognosis for patients with pancreatic cancer. MethodsSerum tumor markers CA199, CA242, CEA, and CA125 of 63 patients with pancreatic cancer, 33 patients with cancer of bile duct, and 27 patients with benign pancreatic disease were detected, and those patients were followed up after operation. ResultsThe levels of CA19-9, CA242, CEA, and CA125 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic disease and cancer of bile duct (Plt;0.05). The sensitivity of CA19-9 alone was the highest in the four tumor markers for the patients with pancreatic cancer 〔79.4% (50/63)〕, but the specificity (61.9%) was lower than that of CA242 (83.3%) and CEA (80.0%). The specificity of combined detection of CA199+CA242+CEA was the highest 〔93.3% (56/60)〕. The level of CA19-9 in carcinoma of body/tail of pancreas was significantly higher than that of carcinoma of pancreas head or whole pancreas (Plt;0.05). The serum levels of CA19-9 and CA242 in patients with stage Ⅳ were significantly higher than those in stage Ⅰ or Ⅱ/Ⅲ (Plt;0.05). Fifteen patients were lost to follow up, 48 patients were followed up 2－12 months with an average 6 months. The levels of CA242 and CA199 in patients with pancreatic cancer on 0.5 month and 3 months after operation were lower than those before operation (Plt;0.05). ConclusionsSingle detection of CA19-9 can improve the diagnostic sensitivity, and combined detection of tumor markers CA199+CA242+CEA can improve the diagnostic specificity. CA19-9 or CA242 is a valuable marker for evaluating treatment effects and estimating prognosis.